Roche Finance Ltd 13D and 13G filings for Entrada Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 3:47 pm Sale |
2024-12-31 | 13G | Entrada Therapeutics, Inc. TRDA |
Roche Finance Ltd | 2,569,115 6.900% |
-175,005 (-6.38%) |
Filing |
| 2024-02-14 4:12 pm Sale |
2023-12-31 | 13G | Entrada Therapeutics, Inc. TRDA |
Roche Finance Ltd | 2,744,120 8.200% |
-69,405 (-2.47%) |
Filing |
| 2022-02-14 06:19 am Purchase |
2021-12-31 | 13G | Entrada Therapeutics, Inc. TRDA |
Roche Finance Ltd | 2,813,525 9.000% |
2,813,525 (New Position) |
Filing |